Table 5.
Standardised incidence ratios (SIR) for developing a primary uveal melanoma following another primary malignancy according to the latency; SIR (95% CIs)
| Characteristics | <5 years | 5–10 years | >10 years | Total* | ||||
| Obs. | SIR (95% CI) | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) | |
| Overall | 166 | 1.08 (0.92 to 1.25) | 132 | 1.20† (1.01 to 1.43) | 143 | 0.99 (0.84 to 1.17) | 441 | 1.08 (0.98 to 1.19) |
| Sex | ||||||||
| Male | 96 | 1.04 (0.84 to 1.27) | 77 | 1.21 (0.95 to 1.51) | 69 | 0.99 (0.77 to 1.25) | 242 | 1.07 (0.94 to 1.21) |
| Female | 70 | 1.13 (0.88 to 1.43) | 55 | 1.20 (0.91 to 1.57) | 74 | 0.99 (0.78 to 1.25) | 199 | 1.09 (0.95 to 1.26) |
| Race | ||||||||
| White | 164 | 1.08 (0.92 to 1.26) | 130 | 1.20† (1.01 to 1.43) | 141 | 0.99 (0.83 to 1.17) | 435 | 1.08 (0.98 to 1.19) |
| Black | 1 | 1.21 (0.03 to 6.75) | 0 | 0 | 1 | 1.59 (0.04 to 8.87) | 2 | 1.00 (0.12 to 3.62) |
| Other races | 0 | 0 | 2 | 4.36 (0.53 to 15.76) | 1 | 1.73 (0.04 to 9.61) | 3 | 1.75 (0.361 to 5.12) |
| Age at diagnosis of the first cancer | ||||||||
| <50 years | 7 | 0.80 (0.32 to 1.65) | 18 | 1.78† (1.06 to 2.82) | 40 | 1.06 (0.76 to 1.45) | 65 | 1.15 (0.89 to 1.47) |
| 50–70 years | 79 | 1.01 (0.80 to 1.26) | 74 | 1.15 (0.91 to 1.45) | 89 | 1 (0.80 to 1.23) | 242 | 1.05 (0.92 to 1.19) |
| >70 years | 80 | 1.18 (0.94 to 1.47) | 40 | 1.13 (0.81 to 1.54) | 14 | 0.78 (0.43 to 1.31) | 134 | 1.11 (0.93 to 1.31) |
| Primary site of uveal melanoma‡ | ||||||||
| Choroid | 137 | 1.04 (0.87 to 1.23) | 111 | 1.17 (0.96 to 1.409) | 117 | 0.93 (0.77 to 1.11) | 365 | 1.04 (0.93 to 1.15) |
| Ciliary body | 29 | 1.28 (0.86 to 1.84) | 21 | 1.43 (0.88 to 2.18) | 26 | 1.43 (0.93 to 2.09) | 76 | 1.37† (1.08 to 1.71) |
| Site of the first malignancy§ | ||||||||
| Breast | 32 | 1.26 (0.86 to 1.776) | 24 | 1.16 (0.75 to 1.73) | 41 | 1.24 (0.89 to 1.69) | 97 | 1.23 (0.995 to 1.5) |
| Prostate | 49 | 1.15 (0.85 to 1.51) | 45 | 1.40† (1.02 to 1.88) | 22 | 0.82 (0.52 to 1.25) | 116 | 1.14 (0.94 to 1.37) |
| Colon and rectum | 18 | 0.96 (0.57 to 1.52) | 15 | 1.19 (0.67 to 1.96) | 21 | 1.29 (0.80 to 1.98) | 54 | 1.14 (0.85 to 1.48) |
| Lung and bronchus | 5 | 0.61 (0.2 to 1.42) | 3 | 0.89 (0.18 to 2.61) | 4 | 1.29 (0.35 to 3.3) | 12 | 0.82 (0.42 to 1.43) |
| Urinary bladder | 12 | 1.18 (0.61 to 2.07) | 6 | 0.84 (0.31 to 1.83) | 9 | 1.00 (0.46 to 1.89) | 27 | 1.03 (0.68 to 1.49) |
| Melanoma of the skin | 11 | 1.56 (0.78 to 2.8) | 10 | 1.75 (0.84 to 3.23) | 17 | 1.59 (0.92 to 2.54) | 38 | 1.62† (1.15 to 2.22) |
| Corpus uteri | 8 | 1.3 (0.56 to 2.55) | 2 | 0.38 (0.05 to 1.37) | 6 | 0.58 (0.21 to 1.27) | 16 | 0.74 (0.42 to 1.2) |
| Non-Hodgkin's lymphoma | 5 | 0.85 (0.28 to 1.98) | 3 | 0.78 (0.16 to 2.27) | 3 | 0.68 (0.14 to 1.99) | 11 | 0.78 (0.39 to 1.39) |
| Oral cavity and pharynx | 5 | 1.25 (0.41 to 2.29) | 3 | 1.12 (0.23 to 3.27) | 2 | 0.55 (0.07 to 2.00) | 10 | 0.97 (0.47 to 1.79) |
| Thyroid | 1 | 2.23 (0.72 to 5.19) | 0 | 2.57 (0.84 to 6.00) | 1 | 0.44 (0.05 to 1.59) | 2 | 1.38 (0.71 to 2.40) |
| Ovary | 5 | 2.92 (0.95 to 6.83) | 1 | 1.00 (0.03 to 5.56) | 3 | 1.43 (0.30 to 4.24) | 9 | 1.88 (0.86 to 3.58) |
| Leukaemia | 2 | 0.57 (0.07 to 2.05) | 6 | 2.92† (1.07 to 6.35) | 1 | 0.5 (0.01 to 2.78) | 9 | 1.19 (0.54 to 2.25) |
| Kidney and renal pelvis | 3 | 0.77 (0.16 to 2.25) | 3 | 1.14 (0.23 to 3.32) | 1 | 0.32 (0.01 to 1.81) | 7 | 0.73 (0.29 to 1.5) |
| Eye and orbit | 1 | 9.96 (0.25 to 55.43) | 0 | 0 | 1 | 9.63 (0.24 to 53.66) | 2 | 7.36 (0.89 to 26.60) |
*Single patient may have multiple tumours. Further details are available in (online supplemental table 10).
†Significant with p<0.05.
‡Using primary site variable.
§Using ICD-O-3 site recode.
ICD, International Classification of Diseases; Obs., observed.